Full Press Release Details
Personalis Reports Second Quarter 2022 Financial Results
MENLO PARK, Calif. - August 3, 2022 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2022.
Second Quarter and Recent Highlights
"We are pleased with the pace of our oncology revenue growth compared with last year, as well as the continued adoption of our NeXT Platform, which is driven by the differentiation and strength of our offerings," said John West, Chief Executive Officer of Personalis. "We are making solid progress on our strategic priorities, with the goal of becoming the leading provider of the most comprehensive and actionable cancer genomic tests. Ultimately, we aim to enable a new standard of oncology care to help patients live better and longer lives."
Second Quarter 2022 Financial Results
Full Year 2022 Outlook
Personalis expects the following for the full year of 2022:
Webcast and Conference Call Information
Personalis will host a conference call to discuss the second quarter 2022 financial results after market close on Wednesday, August 3, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique personal PIN that can be used to join the call. The live webinar can be accessed at https://investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "aim," "continue to," "expect," "future," "goal," or "will" or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements regarding the company's full year financial guidance, the company's business outlook and the company's goals and aims. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Personalis' actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers, including from Natera, which accounted for 38% of the company's total revenue in the second quarter of 2022; the launch and market adoption of new products and new product features, such as NeXT Personal; the timing of tissue, blood, and other specimen sample receipts from customers, which can materially impact revenue quarter-over-quarter and year-over-year; whether orders for the NeXT Platform and revenue from biopharmaceutical customers and Natera increase or decrease in future periods; attributes or advantages of NeXT Personal or the Personalis NeXT Platform; the expected benefits or success of Personalis' collaborations including with Mayo Clinic and University of California, San Diego; the success of the company's international expansion plans; the evolution of cancer therapies and market adoption of the company's services; the ongoing COVID-19 pandemic, which may significantly impact the company's business and operations and the business and operations of Personalis' customers and suppliers; and legal proceedings to enforce patents, and the presumed
validity or enforceability of the company's patents or other intellectual property rights. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, filed with the Securities and Exchange Commission (SEC) on May 4, 2022, and in Personalis' Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2022, being filed with the SEC today. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
Investor Relations Contact:
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | $ | 18,240 | $ | 21,670 | $ | 33,467 | $ | 42,551 | ||||||||
| Costs and expenses | ||||||||||||||||
| Cost of revenue | 13,959 | 13,502 | 24,908 | 26,956 | ||||||||||||
| Research and development | 16,288 | 11,687 | 33,386 | 21,183 | ||||||||||||
| Selling, general and administrative | 15,874 | 11,428 | 31,360 | 21,849 | ||||||||||||
| Total costs and expenses | 46,121 | 36,617 | 89,654 | 69,988 | ||||||||||||
| Loss from operations | (27,881 | ) | (14,947 | ) | (56,187 | ) | (27,437 | ) | ||||||||
| Interest income | 349 | 103 | 493 | 198 | ||||||||||||
| Interest expense | (50 | ) | (65 | ) | (109 | ) | (65 | ) | ||||||||
| Other income (expense), net | 50 | (36 | ) | 69 | (48 | ) | ||||||||||
| Loss before income taxes | (27,532 | ) | (14,945 | ) | (55,734 | ) | (27,352 | ) | ||||||||
| Provision for income taxes | 14 | 8 | 21 | 5 | ||||||||||||
| Net loss | $ | (27,546 | ) | $ | (14,953 | ) | $ | (55,755 | ) | $ | (27,357 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.60 | ) | $ | (0.34 | ) | $ | (1.23 | ) | $ | (0.63 | ) | ||||
| Weighted-average shares outstanding, basic and diluted | 45,637,838 | 43,960,794 | 45,316,795 | 43,113,195 |
SUPPLEMENTAL REVENUE INFORMATION (unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| VA MVP | $ | 4,055 | $ | 13,507 | $ | 7,556 | $ | 26,717 | ||||||||
| All other customers | 14,185 | 8,163 | 25,911 | 15,834 | ||||||||||||
| Total revenue | $ | 18,240 | $ | 21,670 | $ | 33,467 | $ | 42,551 |
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands, except share and per share data)
| June 30, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 86,731 | $ | 105,585 | ||||
| Short-term investments | 146,759 | 181,479 | ||||||
| Accounts receivable, net | 12,877 | 18,468 | ||||||
| Inventory and other deferred costs | 7,885 | 5,610 | ||||||
| Prepaid expenses and other current assets | 5,788 | 7,089 | ||||||
| Total current assets | 260,040 | 318,231 | ||||||
| Property and equipment, net | 47,585 | 19,650 | ||||||
| Operating lease right-of-use assets | 45,915 | 53,822 | ||||||
| Other long-term assets | 4,439 | 4,825 | ||||||
| Total assets | $ | 357,979 | $ | 396,528 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 21,395 | $ | 9,221 | ||||
| Accrued and other current liabilities | 19,755 | 18,110 | ||||||
| Contract liabilities | 356 | 3,982 | ||||||
| Total current liabilities | 41,506 | 31,313 | ||||||
| Long-term operating lease liabilities | 51,836 | 52,797 | ||||||
| Other long-term liabilities | 5 | 2,117 | ||||||
| Total liabilities | 93,347 | 86,227 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' equity | ||||||||
| Preferred stock, $0.0001 par value - 10,000,000 shares authorized; none issued | - | - | ||||||
| Common stock, $0.0001 par value - 200,000,000 shares authorized; 45,891,458 and 44,904,512 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 5 | 4 | ||||||
| Additional paid-in capital | 568,741 | 557,558 | ||||||
| Accumulated other comprehensive loss | (1,264 | ) | (166 | ) | ||||
| Accumulated deficit | (302,850 | ) | (247,095 | ) | ||||
| Total stockholders' equity | 264,632 | 310,301 | ||||||
| Total liabilities and stockholders' equity | $ | 357,979 | $ | 396,528 |